About Us

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.

This Financial Times webinar has been funded by and developed in partnership with Daiichi Sankyo, a pharmaceutical company specialising in oncology and speciality medicines.

This fact sheet has been produced by the Acute Leukaemia Advocates Network (ALAN). ALAN is an independent global network of patient organisations, dedicated to changing outcomes of patients with acute leukaemia.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice